SCHEMBL27030601

SCHEMBL27030601

CCOC(=O)c1cccc(NC(=O)c2sccc2S(=O)(=O)N(C)c2ccc(OCC)cc2)c1

nearest known ligand 0.89

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SREBF1 P36956 14/20 0.89
NR1H3 Q13133 11/20 0.89
NR1H2 P55055 11/20 0.89
NPC1 O15118 3/20 0.57
MAPT P10636 3/20 0.57
RAB9A P51151 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
MAPK1 P28482 2/20 0.54
LMNA P02545 2/20 0.54
ALDH1A1 P00352 1/20 0.54
HSD17B10 Q99714 2/20 0.52
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27030539 0.94 SREBF1 (1.00) SREBF1NR1H3NR1H2NPC1MAPT
SCHEMBL27245358 0.94 SREBF1 (0.85) SREBF1NR1H3NR1H2NPC1MAPT
SCHEMBL27245361 0.93 SREBF1 (0.89) SREBF1NR1H3NR1H2NPC1MAPT
SCHEMBL29944859 0.93 SREBF1 (0.89) SREBF1NR1H3NR1H2NPC1MAPT
SCHEMBL27030659 0.92 SREBF1 (0.76) SREBF1NR1H3NR1H2NPC1MAPT
SCHEMBL27245378 0.92 SREBF1 (0.89) SREBF1NR1H3NR1H2NPC1MAPT
SCHEMBL27030433 0.92 SREBF1 (0.75) SREBF1NR1H3NR1H2NPC1RAB9A
SCHEMBL29944875 0.92 SREBF1 (0.75) SREBF1NR1H3NR1H2NPC1RAB9A
SCHEMBL29944840 0.91 SREBF1 (0.75) SREBF1NR1H3NR1H2NPC1MAPT
SCHEMBL29944868 0.91 SREBF1 (0.80) SREBF1NR1H3NR1H2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199572-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-20 US disclosed
EP-4308554-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA The Board of Trustees of the University of Illinois (US) 2024-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199572-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA SREBF2, SREBF1, SLC2A2 SREBF1 2/4885NR1H3 21/4885NR1H2 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.